戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 eta2-agonist plus short-acting beta2-agonist reliever.
2 eta2-agonist plus short-acting beta2-agonist reliever.
3 intenance plus short-acting beta2-agonist as reliever.
4 dicines antibacterials and pain and migraine relievers.
5 ent a promising new generation of novel pain relievers.
6  endorphins and enkephalins, are potent pain relievers.
7 ally acceptable for an over-the-counter pain reliever?
8 s powerful and reversible topological stress relievers, an insight that significantly expands the rep
9 theast Asia, are increasingly used as a pain reliever and for attenuation of opioid withdrawal sympto
10       Decreases in use were smaller for pain relievers and antidepressants and larger for acid suppre
11 nt the largest and most potent class of pain relievers available to treat both acute and chronic pain
12 orly adherent patients who overrely on their reliever beta-agonist inhaler.
13 hen (APAP) is a commonly used pain and fever reliever but is also the most frequent cause of drug-ind
14                  Morphine is a powerful pain reliever, but also a potent inducer of tolerance and dep
15 en admitted to hospitals with asthma receive relievers (CAC-1) and systemic corticosteroids (CAC-2) a
16 , a vasodilator, anti-inflammatory, and pain reliever, could alter the pathophysiology of sickle cell
17 is a prime target in the development of pain relievers.FUNDINGSupported by the Israel Science Foundat
18                       Administration of pain relievers has been associated with both lower and higher
19  maintenance plus short-acting beta2-agonist reliever (hazard ratio, 0.71; 95% CI, 0.52-0.97).
20          Opioid analgesics are powerful pain relievers; however, over time, pain control diminishes a
21 he chronic usefulness of this excellent pain reliever in man.
22  indomethacin, the drugs widely used as pain relievers in the clinic, can surmount axon growth restri
23 symptom scores (visual analogue scale, VAS), reliever medication use and medication-free days (MFD).
24 bation rate, ACQ-6, asthma symptom scores or reliever medication use.
25 influence perception has on patients' use of reliever medication.
26  in FEV1, symptoms, and use of supplementary reliever medication.
27               Combined anti-inflammatory and reliever medications in a single inhaler have the potent
28 reatment and iatrogenic adverse effects with reliever medications, anxiety, and unnecessary use of he
29 fected patients, particularly with regard to reliever medications.
30 edication dispensations, and dispensation of reliever medications.
31 elief (sometimes referred to as "rescue" or "reliever") medications.
32 velopment of TRPV1 antagonists as novel pain relievers.METHODSWe examined 2 affected individuals (A1
33 , firearm ownership (beta = 0.030), and pain reliever misuse (beta = 1.131).
34 ldren aged 5-15 years with asthma using SABA reliever monotherapy at 15 clinical trials sites in New
35 pared to short-acting beta(2)-agonist (SABA) reliever monotherapy in adults.
36 ears with mild asthma, budesonide-formoterol reliever monotherapy is superior to salbutamol for preve
37 ombination inhaled corticosteroid-formoterol reliever monotherapy reduces the rate of asthma attacks
38  separate studies to be either an inducer or reliever of oxidative stress, and this contradiction has
39  vitamin D-deficient mice with the ER stress reliever PBA during HF feeding suppressed atherosclerosi
40 higher-level medication, of whom half had no reliever prescription or exacerbation in the year prior.
41 .00, 0.91-1.09, p = 0.79) and no increase in reliever prescriptions (adjusted odds ratio, 95% CI, p-v
42 spectively, exacerbations and an increase in reliever prescriptions.
43 or ICS/long-acting beta-agonist inhaler as a reliever rather than regular maintenance use.
44 f antiepileptic drug (R)-lacosamide and pain reliever (S)-lacosamide on a large scale has been articu
45 costeroid-formoterol as both maintenance and reliever (SMART) or inhaled corticosteroid-long-acting b
46 aled steroids, the Symbicort maintenance and reliever (SMART) regimen (with budesonide and formoterol
47 with a fixed-dose regimen with salbutamol as reliever ('Standard'), actual medication use was measure
48 ated hCA IX but also potent neuropathic pain relievers targeting hCA VII.
49       Thus, vitamin D is a natural ER stress reliever that induced an antiatherogenic monocyte/macrop
50 on beclomethasone/formoterol maintenance and reliever therapy (baseline), participants with uncontrol
51 udesonide-formoterol inhaler Maintenance And Reliever Therapy (SMART) regimen reduces severe asthma e
52                          The optimal inhaled reliever therapy for asthma remains unclear.
53 costeroid and long-acting beta(2)-agonist as reliever therapy in addition to maintenance treatment.
54 ence supporting the use of anti-inflammatory reliever therapy in mild asthma and the implementation o
55 ayers medicated for asthma/EIB (a third with reliever therapy only) do not present reversible airway
56    Beclomethasone/formoterol maintenance and reliever therapy requirement was reduced at 12 weeks ver
57 l approach to mild asthma has long relied on reliever therapy with as-needed short-acting beta-agonis
58 ild asthma have shown that anti-inflammatory reliever therapy with budesonide-formoterol, given on an
59 paring budesonide/formoterol maintenance and reliever therapy with fixed-dose inhaled corticosteroid/
60  in a single inhaler (single maintenance and reliever therapy) is recommended as the preferred therap
61 o budesonide plus formoterol maintenance and reliever therapy, fixed-dose budesonide plus formoterol,
62 eta2-agonist plus short-acting beta2-agonist reliever therapy.
63 to-severe asthma to use a patient-activated, reliever-triggered inhaled glucocorticoid strategy (becl
64 ry events based on peak expiratory flow (P), reliever use (R), symptoms (S), awakenings (A), and thre
65       In the sole investigation of male pain-reliever use and human fertility carried out to date, Sm
66  0.74, 95% CI 0.72-0.77), defined as limited reliever use and no asthma-related hospital attendance o
67 g down medication increased exacerbations or reliever use, as well as its impact on costs.
68 stionnaire-five-item version, exacerbations, reliever use, FEV(1), peak expiratory flow, or fractiona
69         On multivariate analysis, GINA step, reliever use, postbronchodilator FEV1, and 5-item Asthma
70           Main outcomes were controller use, reliever use, unscheduled doctor visits, emergency depar
71 ences (P < 0.05) in domiciliary symptoms and reliever use.
72 ompared with SABA alone, both ICS-containing relievers were associated with fewer severe exacerbation
73 ompared with SABA alone, both ICS-containing relievers were associated with improved asthma control (
74   Fentanyl is a potent synthetic opioid pain reliever with a high bioavailability that can be used as